Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection: A Multi-Arm Multi-Stage Randomized Trial (MAMS) to Evaluate the Effectiveness of Several Specific Treatments in Reducing the Risk of Clinical Worsening or Death in Sub-Saharan Africa (COVERAGE-Africa)

Marcy et al., NCT04920838, COVERAGE-A, NCT04920838, Aug 2023

Budesonide for COVID-19

24th treatment shown to reduce risk in September 2021, now with p = 0.000003 from 15 studies, recognized in 10 countries.

No treatment is 100% effective.
Protocols combine treatments.

Estimated 600 patient budesonide early treatment RCT with results not reported over 3 years after estimated completion.
4 budesonide RCTs have results missing long after expected1-4
The trials report a total of 916 patients, with 1 trial having actual enrollment of 146, and the remainder estimated.
Marcy et al., 1 Aug 2023, Randomized Controlled Trial, multiple countries, trial NCT04920838 (history) (COVERAGE-A). Contact: olivier.marcy@u-bordeaux.fr, anthony.lhostellier@u-bordeaux.fr, armelpoda@yahoo.fr, sondoapoline@yahoo.fr.